Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Carcinoma, Hepatocellular 6Pancreatic Neoplasms 4Colorectal Neoplasms 4Liver Neoplasms 3Neoplasm Metastasis 2Melanoma 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Stomach Neoplasms 1Somatostatinoma 1Sarcoma 1Prostatic Neoplasms 1PRETEXT I Hepatoblastoma 1Ovarian Neoplasms 1Neoplasms 1Multiple Myeloma 1Lung Neoplasms 1Kidney Neoplasms 1Hematologic Neoplasms 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Fallopian Tube Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

trametinib 3pertuzumab 3dabrafenib 3Specimen Handling 3Nivolumab 3Bevacizumab 3venetoclax 2palbociclib 2copanlisib 2cobimetinib 2Vemurafenib 2Trastuzumab 2Sunitinib 2Sorafenib 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Leucovorin 2Ipilimumab 2Immunoglobulin G 2HhAntag691 2Fluorouracil 2Disulfides 2Dasatinib 2CTLA-4 Antigen 2Afatinib 2Ado-Trastuzumab Emtansine 22C4 antibody 2vactosertib 1ulixertinib 1trastuzumab biosimilar HLX02 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × temsirolimus × Gastrointestinal × Clear all
NCT01183663 2016-06-03

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

M.D. Anderson Cancer Center

Phase 1 Completed
180 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryOther hematologic neoplasmPlasma cell

Breast Neoplasms, Carcinoma, Renal Cell, Colonic Neoplasms, Glioblastoma, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡